Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type! d! t$ f& B) |5 t
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, {! ?" @" U+ r+ Author Affiliations
8 b# b' f, Y5 K8 i7 D8 }' r+ c% x! v. r) L* ~( Z# M8 w
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
+ S) U4 K8 D% Q- N2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan * V6 N1 }0 Y/ y( h
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
2 l# D$ P! h* {* o2 U; n& U2 v. t$ Y4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
: N) z7 j$ v% |* }5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
0 t6 i: K" h4 O/ q7 Y' q6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 6 V8 V4 K L2 X9 V% _& Q6 R' }
7Kinki University School of Medicine, Osaka 589-8511, Japan
5 q% a; m2 Q, ?. v# a8Izumi Municipal Hospital, Osaka 594-0071, Japan ( M) `. u) b1 o: `6 Z, B; k6 k
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan " c* B/ t9 v5 x5 X$ H3 H. @1 U
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp * m$ i! u$ O- z' j2 _
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. " i* |+ H. W* `
- I" ?$ ~+ ]' `: \& w( K3 {9 T |